Exposure to animal-derived medical products can lead to the development of circulating anticoagulants against animal plasmas, which may confound laboratory coagulation assays without causing clinical symptoms.
Answers are grounded in this paper and cite their sources.
Artifactual anticoagulants from animal-product exposure may confound animal-substrate assays without clinical effect; leaves open prevalence and standardized detection.
A circulating anticoagulant against bovine, equine, guinea pig, and sheep plasmas developed in a 15-year-old cardiac patient. He had been exposed to both bovine and porcine heparin over a period of 13 years, and had a porcine valve placed four years before the anticoagulant was noted. There was no anticoagulant activity detected against human, rat, or porcine plasma, and an equivocal reaction against rabbit plasma. There was no apparent clinical significance to the anticoagulant. It did, however, confuse the interpretation of coagulation factor assays based on animal substrate plasmas.
No takes yet. Share an insight, caveat, or question.
Clyne et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: